Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery
European Journal of Cancer2017Vol. 84, pp. 44–54
Citations Over TimeTop 10% of 2017 papers
Caroline Gaudy‐Marqueste, A.-S. Dussouil, Romain Carron, L. Troin, Nausicaa Malissen, Anderson Loundou, S. Monestier, S. Mallet, M.‐A. Richard, Jean Régis, Jean‐Jacques Grob
Related Papers
- → Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab(2015)3 cited
- → IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA(2016)2 cited
- → Mo1273 Ipilimumab-Induced Colitis in Patients With Metastatic Melanoma(2014)1 cited
- → Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study(2013)
- → CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients.(2016)